Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:ETNB 5 November 2025

Roche’s $3.5B Bet on 89bio (ETNB) – Stock Soars to New Highs as NASH Breakthrough Looms

Roche’s $3.5B Bet on 89bio (ETNB) – Stock Soars to New Highs as NASH Breakthrough Looms

Roche completed its $3.5 billion acquisition of 89bio on Oct. 29, 2025, paying $14.50 per share in cash plus up to $6.00 per share in milestones. ETNB stock hit a 52-week high of $15.06 after the deal, reflecting a 52% premium. 89bio’s lead drug, pegozafermin, is in Phase 3 trials for MASH and SHTG. The company remains pre-revenue, reporting a $149 million net loss over the past year.
5 November 2025
·

Stock Market Today

  • Evertz Technologies Fair Value Targets Lifted by Analysts on TSX
    March 20, 2026, 2:37 PM EDT. Analysts have raised the fair value estimate for Evertz Technologies (TSX:ET) from CA$14.88 to CA$17.25, reflecting a roughly 16% increase and aligning with a cluster of price targets between CA$16 and CA$17.50. Canaccord and BMO Capital have each lifted their price targets to CA$17.50, maintaining positive ratings, while RBC Capital has raised its target incrementally to CA$16 but retains a cautious Sector Perform stance. The upward revisions follow updated assumptions, including a slight dip in revenue growth to 4.16% and an improved net profit margin to 12.98%. The stock's quarterly dividend was declared at CA$0.2050 per share, payable March 2026. Investors should note the narrowed upside range and potential risks flagged, advising careful consideration of entry points and expectations.
Go toTop